XOMA Royalty Corporation
$ 25.55
0.00%
05 Jun - close price
- Market Cap N/A
- Current Price $ 25.55
- High / Low $ 25.55 / 25.55
- Stock P/E 25.52
- Book Value 7.07
- EPS 1.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.34 %
- 52 Week High 28.22
- 52 Week Low 23.51
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
N/A
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-15 | 2026-01-15 | 2025-10-15 | 2025-07-15 | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 | 2024-01-16 |
| Amount | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMAP
2026-04-27 14:38:44
Ligand Pharmaceuticals announced its acquisition of XOMA, a rival biotech royalty firm, for $739 million. This strategic move aims to expand Ligand's portfolio and market position within the biotechnology royalty space. The acquisition signifies a significant consolidation in the sector, bringing together two key players.
2026-04-01 18:40:11
An analysis of Xoma Royalty Corp (XOMA) suggests it is not a strong buy for beginner, long-term investors at this time. While the company saw a significant year-over-year revenue increase in Q4 2025 and has positive analyst ratings, its net income dropped substantially, the stock is overbought by RSI, and it lacks strong trading signals. The article recommends waiting for a better entry point despite some positive analyst price target increases.
2026-03-14 04:38:45
XOMA Royalty Corporation announced it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will also host a webcast on the same day at 8:00 am Eastern Time to discuss the results and provide a business update, which will be accessible on their investor relations website. XOMA Royalty specializes in acquiring future economics from pre-commercial and commercial therapeutic candidates, providing non-dilutive funding to biotech companies.
2026-02-20 01:57:47
XOMA Royalty Corporation has entered into a definitive merger agreement to acquire Turnstone Biologics Corp. for $0.34 in cash per share, plus a non-transferable contingent value right, with the transaction expected to close in August 2025. The Turnstone Board of Directors unanimously approved the acquisition, and a significant portion of Turnstone stockholders have agreed to support the merger. This acquisition is part of XOMA's strategy to expand its biotechnology royalty portfolio.
2026-02-20 01:39:15
XOMA Royalty Corporation (XOMA) offers a compelling investment opportunity in the biotechnology sector through its unique royalty aggregation model. The company acquires rights to milestone and royalty payments from various therapeutic candidates, enabling it to benefit from successful commercial and clinical assets. Analysts project a significant upside potential of 164.89% for XOMA's stock, driven by its robust revenue growth and strategic acquisitions, despite current negative free cash flow.
2026-02-09 09:53:00
XOMA Royalty Corporation has successfully completed its tender offer and acquisition of Generation Bio Co. for $4.2913 per share in cash plus a contingent value right. Approximately 70% of Generation Bio's outstanding shares were tendered, satisfying the minimum conditions. As a result, Generation Bio is now a wholly-owned subsidiary of XOMA Royalty and its shares have ceased trading on Nasdaq, with plans for delisting and deregistration.
